Background/objectives: Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The gene discussed is SYK; the disease is autoimmune thrombocytopenic purpura.